Results 11 to 20 of about 6,491 (191)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children

Drugs in Context, 2015
Background: The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. Additional monthly doses of palivizumab may be necessary in warmer regions to protect
Saleh al-Alaiyan, Paul Pollack, Gerard F Notario   +2 more
doaj   +2 more sources

Palivizumab: Four Seasons in Russia

Annals of the Russian academy of medical sciences, 2014
In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically ...
Baranov A.A., Ivanov D.O., Alyamovskaya G.A., Amirova V.R., Antonyuk I.V., Asmolova G.A., Belyaeva I.A., Bokeriya E.L., Bryukhanova O.A., Vinogradova I.V., Vlasova E.V., Galustyan A.N., Gafarova G.V., Gorev V.V., Davydova I.V., Degtyarev D.N., Degtyareva E.A., Dolgikh V.V., Donin I.M., Zakharova N.I., Zernova L.Yu., Zimina E.P., Zuev V.V., Keshishyan E.S., Kovalev I.A., Koltunov I.E., Korsunskii A.A., Krivoshchekov E.V., Krsheminskaya I.V., Kuznetsova S.N., Lyubimenko V.A., Namazova-Baranova L.S., Nesterenko E.V., Nikolaev S.V., Ovsyannikov D.Yu., Pavlova T.I., Potapova M.V., Rychkova L.V., Safarov A.A., Safina A.I., Skachkova M.A., Soldatova I.G., Turti T.V., Filatova N.A., Shakirova R.M., Yanulevich O.S.   +45 more
core   +7 more sources

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study [PDF]

Frontiers in Pharmacology, 2020
ObjectiveCurrent prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV ...
Anushi E. Rajapaksa, Anushi E. Rajapaksa, Anushi E. Rajapaksa, Lien Anh Ha Do, Lien Anh Ha Do, Darren Suryawijaya Ong, Darren Suryawijaya Ong, Magdy Sourial, Duncan Veysey, Richard Beare, Richard Beare, William Hughes, William Yang, Robert J. Bischof, Robert J. Bischof, Amarin McDonnell, Peter Eu, Leslie Y. Yeo, Paul V. Licciardi, Paul V. Licciardi, Edward K. Mulholland, Edward K. Mulholland, Edward K. Mulholland   +22 more
doaj   +4 more sources

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

BMC Infectious Diseases, 2017
Background This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. Methods A decision-tree
M. Sanchez-Luna, R. Burgos-Pol, I. Oyagüez, J. Figueras-Aloy, M. Sánchez-Solís, F. Martinón-Torres, X. Carbonell-Estrany   +6 more
doaj   +2 more sources

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar

International Journal of General Medicine, 2018
Ahmad Abushahin, Ibrahim Janahi, Amjad Tuffaha Department of Pediatrics, Section of Pediatric Pulmonology, Hamad Medical Corporation, Doha, Qatar Objective: The primary objective of this study was to document the hospitalization rate due to ...
Abushahin A, Janahi I, Tuffaha A
doaj   +1 more source

Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina

Journal of Pediatric and Neonatal Individualized Medicine, 2016
Background: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children. Methods: Observational study, based on 4 sites in Bosnia and Herzegovina (B&H), with institutional reports of infants at high risk for RSV ...
Suada Heljic, Hajrija Maksic, Hidajeta Begic, Fahrija Skokic, Darinka Glamuzina, Tomica Bozic, Stojislav Konjevic, Veroslava Milosevic, Sabina Terzic   +8 more
doaj   +2 more sources

Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease

Journal of Pediatric and Neonatal Individualized Medicine, 2015
Intramuscular injections are contra-indicated in infants with either acquired or congenital bleeding disorders. In such patients, it is unlicensed practice to administer vaccines by subcutaneous route.
Karel Allegaert, Maissa Rayyan, Veerle Cossey, Chris Van Geet   +3 more
doaj   +2 more sources

RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience. [PDF]

Health Sci Rep
ABSTRACT Background New respiratory syncytial virus (RSV) preventative programs are launching globally. Our Australian jurisdiction implemented RSV monoclonal antibody provision via pediatric and perinatal hospitals for highest risk neonates and infants.
Tuckerman J, Cheng DR, Hunter G, Elia S, Hearn T, Verma D, Jacobs S, Carr J, Crawford NW.   +8 more
europepmc   +2 more sources

The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab – validation against two external data sources

Clinical Epidemiology, 2015
Ann Haerskjold,1,2 Lonny Henriksen,2 Susanne Way,1 Mikkel Malham,3 Jesper Hallas,4 Lars Pedersen,5 Lone Graff Stensballe1 1The Child and Adolescent Clinic 4072, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 2The Research Unit Women&#
Haerskjold A, Henriksen L, Way S, Malham M, Hallas J, Pedersen L, Stensballe LG   +6 more
doaj   +1 more source

Palivizumab for Donor-Derived RSV Infection in an Adult Bilateral Lung Transplant Recipient: A Case Report. [PDF]

Respirol Case Rep
We describe the use of off‐label palivizumab in an early post‐operative bilateral lung transplant recipient with probable donor‐derived RSV who developed persistent severe LRTI and respiratory failure. RSV PCR Ct fell and remained low from day 0 to day 42 despite conventional therapy until palivizumab was administered on day 44, following which we ...
Meharry R, Vale C, Mackintosh J.
europepmc   +2 more sources